Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Journal of Perinatology volume 41, pages 2377–2378 (2021)Cite this article

Subjects

Neurodevelopmental data among infants treated for ROP are limited. In the hierarchy of evidence, a meta-analysis may potentially provide higher quality evidence than a single study, and we commend Kaushal et al. for undertaking this important step. A major limitation of pooled data, however, is that results depend upon the quality and size of included studies.

In a meta-analysis, assessing the risk of bias is paramount. The authors used the Modified Newcastle–Ottawa Scale, which, although a convenient assessment of non-randomized studies for risk of bias, does not remove bias. Inclusion of bias in a meta-analysis does not resolve uncertainty but propagates the bias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE. 2020;15:e0230678.

    Article  CAS  Google Scholar 

  2. Blair MP, Shapiro MJ, Ad Hoc Group Concerning Neurodevelopment and antiVEGF. Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844). Ophthalmology. 2017;124:e74–e75.

    Article  Google Scholar 

  3. Rodriguez SH, Blair MP, Shapiro MJ, Berrocal AM, Murray TG, Martinez-Castellanos MA, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics. 2020;145:e20200056A.

    Article  Google Scholar 

  4. Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG, et al. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019;39:1300–8.

    Article  CAS  Google Scholar 

  5. Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126:1567–77.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Chicago, Chicago, IL, USA

    Sarah Hilkert Rodriguez

  2. Retina Consultants, Ltd., The University of Chicago, Chicago, IL, USA

    Michael P. Blair

  3. Retina Consultants, Ltd., The University of Illinois, Chicago, IL, USA

    Michael J. Shapiro

  4. Bascom Palmer Eye Institute, Miami, FL, USA

    Audina M. Berrocal

  5. Calgary Retina Consultants, The University of Calgary, Calgary, AB, Canada

    Anna L. Ells

  6. Emory Eye Center, Atlanta, GA, USA

    G. Baker Hubbard III

  7. Asociacion Para Evitar la Ceguera en Mexico, I.A.P. Hospital “Dr. Luis Sanchez Bulnes”, Cabo San Lucas, Mexico

    Maria Ann Martinez-Castellanos

  8. Murray Ocular Oncology and Retina, Miami, FL, USA

    Timothy G. Murray

  9. Chang Gung Memorial Hospital, Taoyuan, Taiwan

    Wei-Chi Wu

Authors
  1. Sarah Hilkert Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Audina M. Berrocal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna L. Ells
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Baker Hubbard III
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Ann Martinez-Castellanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Timothy G. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei-Chi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Hilkert Rodriguez.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodriguez, S.H., Blair, M.P., Shapiro, M.J. et al. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol 41, 2377–2378 (2021). https://doi.org/10.1038/s41372-021-01133-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-021-01133-3

Search

Advanced search

Quick links